Avidity Biosciences

Historical price data

Avidity Biosciences is revolutionizing RNA therapeutics through its proprietary AOC platform, which enables targeted delivery to previously inaccessible tissues and cell types. The company's lead programs address the root causes of rare muscle diseases, with clinical data reported for DM1, FSHD, and DMD. As a publicly traded company with an $11.2 billion market valuation, Avidity represents a significant player in the emerging RNA therapeutics space, leveraging proven antibody and oligonucleotide technologies to create first-in-class treatments for underserved patient populations.

Antibody Oligonucleotide Conjugates (AOCs) platform that combines the specificity of monoclonal antibodies with the precision of oligonucleotides to deliver RNA therapeutics to previously inaccessible tissue and cell types.

10 drugs in pipeline, 3 in Phase 3

Total raised: $427M

Avidity competes in the RNA therapeutics space against companies developing antisense oligonucleotides, siRNA, and other RNA approaches, but differentiates through its unique AOC platform enabling tissue-specific targeting. Key advantage lies in combining proven antibody targeting with oligonucleotide precision to access previously undruggable tissues.